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Material and Methods: Syngenic C57BL/6 mice were 
subcutaneously injected with ovalbumin-expressing murine 
thymoma cells (E.G7-OVA, 3×105) into the right hind leg of on 
day -13 and into the left flank on day -9. On days 0, 1 and 2, 
the primary tumors (right hind leg) were irradiated (IR) with 
fractions of 2 Gy photons by the use of a linear accelerator. 
The secondary tumors at the left flank were shielded and 
received only 1.1 ± 0.3% of the IR dose applied to the primary 
tumor as confirmed by film dosimetry. Twice per week, 
tumor length and width were measured by caliper for tumor 
volume calculation and vaccination groups were 
intradermally injected with the mRNA-based vaccine 
RNActive® encoding Ovalbumin beginning day 0. At the end 
of the experiments, the secondary tumors were analyzed for 
cytokine abundances by protein microarray. 
 
Results: Primary and secondary tumors of control mice 
developed with similar growth kinetics. IR and combined 
radioimmunotherapy significantly delayed tumor growth 
leading to primary tumor control in 15% and 53% of mice. 
Importantly, in secondary tumors with starting volumes below 
30mm³ radioimmunotherapy induced a significant growth 
delay compared to vaccination alone (p=0.002) and control 
group (p=0.01). IR alone delayed the growth of the 
secondary, unirradiated tumors in an unsignificant manner. 
Cytokine microarray analysis of the unirradiated secondary 
tumors showed significant differences in combined 
radioimmunotherapy for CCL5/RANTES and CXCL9/MIG 
expression as compared to the other groups, both suggesting 
increased T-cell activation. Similar but unsignificant trends 
could be observed for TNF-α, CCL3, IL-1α, VEGF, M-CSF and 
other cytokines. 
 
Conclusion:  
Immunotherapy can enhance radiation-induced abscopal 
effects in small immunogenic tumors. This effect exhibits the 
potential of a combined radioimmunotherapy for the control 
of micrometastases. The characterization of the underlying 
immunological processes has to await further experiments. 
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Developments in high-precision radiotherapy by means of on-
board imaging, such as IMRT and stereotactic radiotherapy, 
have extended the possibilities for dose escalation to tumor 
localizations, while de-escalating doses to surrounding 
normal tissues. Advances in imaging technologies allow for 
better differentiation of tumor extension and target 
localization. In addition to superior anatomical imaging 
possibilities, functional and molecular imaging can be utilized 
to convey information regarding inherent tumor 
characteristics relevant for prognostication and prediction of 
therapy response. In many different tumor types, studies 
have investigated the potential of especially magnetic 
resonance imaging (MRI) and positron emission tomography 
(PET) / computed tomography (CT) scan to bring various 
tumor features to light. Repetitive imaging of malignancies 
before and during treatment can give rise to response 
adaptive treatment as has been successfully shown by 
integrating 18F-Fluorodeoxyglucose (18F-FDG) PET/CT 
imaging in chemotherapy response evaluation of Hodgkin’s 
Lymphoma, in order to define the eventual radiotherapy 
target and dose or to avoid radiotherapy altogether. For 
response evaluation of Hodgkin’s Lymphoma on 18F-FDG 
PET/CT images, application of the internationally accepted 
Deauville criteria reduce interobserver variability and 
standardize response criteria. 
In many solid tumor types, numerous mostly single-center 
studies have described a plethora of functional or molecular 
imaging characteristics for description of tumor features, 
prognostication and prediction purposes, radiotherapy target 
delineation or direction of targeted therapy. This illustrates 
the drive towards personalized medicine in oncology, where 
individual therapy and therapy adaptation are based on 
specific patient and tumor characteristics. PET/CT studies 
concerning prognostic and predictive imaging properties have 
focused on depiction of tumor characteristics and their 
changes during therapy; such as metabolism (e.g. 18F-FDG 
PET), hypoxia (e.g. 18F-fluoromisonidazole PET, 18F-
fluoroazomycin arabinosine PET, Blood Oxygen Level-
dependent MRI), proliferation (e.g. 18F-fluorothymidine 
PET), cell membrane synthesis (e.g. 11C-choline PET), tumor 
cellularity (e.g. Diffusion-weighted MRI) or tumor perfusion 
(e.g. Dynamic Contrast-enhanced MRI). Clinical and pre-
clinical PET/CT studies have illustrated the possibility to 
quantify presence and abundance of targets for antibody-
based therapies, such as radiolabeled cetuximab in the case 
of the epidermal growth factor receptor. Studies on adaptive 
radiotherapy based on PET/CT imaging, in e.g. head-and-
neck squamous cell carcinoma and non-small cell lung 
cancer, have mainly focused on definition of radiotherapy-
resistant tumor subvolumes relevant for dose-escalation. 
Longer follow up results of these studies will reveal if these 
therapy intensifications will lead to better disease outcomes.  
What such imaging studies bring forward, is that different 
imaging modalities with different specific biological markers 
will define different tumor subvolumes, mostly with different 
spatial and temporal properties. The challenge is to define 
the correct individual therapy regulations for the correct 
tumor within the correct timeframe. Moreover, how can one 
reliably quantify the imaging signal, delineate radioresistant 
tumor subvolumes or evaluate therapy response, if most 
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studies use local institutional approaches to manage imaging 
information for these purposes?  
All these issues need to be resolved before widespread 
implementation into clinical practice can take place. 
Molecular and functional imaging and its evaluation has to be 
validated and proven to be useful in multicenter studies. 
Advanced solutions need to be established to incorporate 
multiparameter information from e.g. tumor biopsy 
immunohistochemical analysis and gene-arrays into decision-
making processes for specific imaging modalities, 
individualized treatment and treatment evaluation pathways. 
The first multicenter studies with these goals in mind are 
now being established. 
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Changes in the tumoras well as normal tissues and organs 
surrounding the tumor during and/or in response to radiation 
therapy require treatmentadaptation. A need for adaptive 
radiation therapy (ART) is not obvious for alltumors, but 
head-and-neck cancer, for which substantial changes in 
tumor andparotid gland geometry and dosimetry have been 
shown [1]. Moreover, biologicchanges in the tumor may 
require treatment adaptationas well [2]. Logistics of ARTis 
complex and hampered by a lack of personnel and robust 
technical tools. Theworkflow is usually not well-defined and 
well-supported by commercial oncologyinformation and 
treatment planning systems. Nevertheless, an increasing 
numberof academic centers introduce ART in their practice 
as has done it inDepartment of Radiotherapy, Ghent 
University Hospital. In this talk theworkflow of ART for head-
and-neck cancer on the example of this particularcenter will 
be discussed in more detail including the roles of personnel 
withemphasis on RTTs, their current responsibilities and their 
possible empowermentin the frame of ART.  
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In the ARTForce project, two international clinical trials are 
conducted. The first trial (NCT01504815) for locally advanced 
head-and-neck cancer patients is a phase two trial 
randomizing between standard chemo-radiotherapy, 
redistributing the dose in the PTV of the primary tumor. 
Instead of a homogeneous dose of 70Gy in 35 fractions, an 
inhomogeneous dose is optimized based with a minimum dose 
of 64 Gy at the edge of the PTV and a maximum dose of 84 
Gy around the FDG PET SUVmax location. Additionally, in the 
experimental arm, the treatment plan is adapted after two 
weeks to account for anatomical changes. The second phase 
2 trial (NCT01024829) for locally advanced lung cancer 
patients randomizes between dose escalation to the primary 
tumor >= 72 Gy in 24 fractions and dose escalation to the 
region of the tumor defined by the 50% of FDG PET SUVmax. 
Both treatment plans are optimized to have an equal mean 
lung dose. In this presentation, dosimetric differences 
between the arms in both trials will be discussed as well as 
the impact of anatomical changes on the delivered dose and 
the effectiveness of replanning to mitigate dose 
discrepancies. 
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Second cancers are an important cause of morbidity and 
mortality in cancer survivors. One in five cancers diagnosed 
in the US are now second cancers. The causes of second 
cancers include lifestyle factors, genetic predisposition and 
also the treatment for the first cancer, including 
radiotherapy. In the last decade there have been a large 
number of new studies that have advanced our understanding 
of the risk of second cancers after radiotherapy. The most 
informative studies provide dose-response relationships based 
on individual dose-reconstruction. These studies suggest that 
the second cancer risk generally increases linearly with dose, 
even at organ doses of ≥60Gy. This is contrary to earlier 
theories that the dose-response would flatten or even have a 
down-turn at higher doses because of cell killing. The 
magnitude of the risk from these fractionated high-dose 
exposures is, however, 5-10 times lower than the risk from 
acute exposures of <2Gy among the Japanese atomic bomb 
survivors. The results from these detailed observational 
studies provide insights into radiation carcinogenesis from 
fractionated high-dose exposures, and can be used to develop 
second solid cancer risk projection models for newer 
radiotherapy techniques. 
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In developed countries, more than half of all cancer patients 
receive radiotherapy at some stage in the management of 
their disease. However, a radiation-induced secondary 
malignancy can be the price of success if the primary cancer 
is cured or at least controlled. Therefore, there is increasing 
concern regarding radiation-related second cancer risks in 
long-term radiotherapy survivors and a corresponding need to 
be able to predict cancer risks at high radiation doses. Of 
particular interest are second cancer risk estimates for new 
radiation treatment modalities such as intensity modulated 
radiotherapy, intensity modulated arc-therapy, proton and 
heavy ion radiotherapy. The long term risks from such 
modern radiotherapy treatment techniques have not yet 
been determined and are unlikely to become apparent for 
many years, due to the long latency time for solid tumor 
induction. Most information on the dose-response of 
radiation-induced cancer is derived from data on the A-bomb 
survivors who were exposed to gamma-rays and neutrons. 
Since, for radiation protection purposes, the dose span of 
main interest is between zero and one Gy, the analysis of the 
A-bomb survivors is usually focused on this range. With 
increasing cure rates, estimates of cancer risk for doses 
larger than one Gy are becoming more important for 
